Induced pluripotent stem cells in Alzheimer’s disease: applications for disease modeling and cell-replacement therapy
- 7.1k Downloads
Alzheimer's disease (AD) is the most common cause of dementia in those over the age of 65. While a numerous of disease-causing genes and risk factors have been identified, the exact etiological mechanisms of AD are not yet completely understood, due to the inability to test theoretical hypotheses on non-postmortem and patient-specific research systems. The use of recently developed and optimized induced pluripotent stem cells (iPSCs) technology may provide a promising platform to create reliable models, not only for better understanding the etiopathological process of AD, but also for efficient anti-AD drugs screening. More importantly, human-sourced iPSCs may also provide a beneficial tool for cell-replacement therapy against AD. Although considerable progress has been achieved, a number of key challenges still require to be addressed in iPSCs research, including the identification of robust disease phenotypes in AD modeling and the clinical availabilities of iPSCs-based cell-replacement therapy in human. In this review, we highlight recent progresses of iPSCs research and discuss the translational challenges of AD patients-derived iPSCs in disease modeling and cell-replacement therapy.
KeywordsAlzheimer’s disease Cell-replacement therapy Disease modeling Drugs screening Induced pluripotent stem cells
active glycogen synthase kinase-3β
Amyloid precursor protein
Clustered regularly interspaced short palindromic repeats
Duplication of APP
Embryonic stem cells
Forebrain cholinergic neuron
Induced pluripotent stem cells
Neural progenitor cells
Octamer-binding transcription factor 4
Sex determining region Y-box
Transcription activator-like effector nucleases
Alzheimer’s disease (AD) is the most common form of dementia that begins with short-term memory deficits and culminates in total loss of cognition and executive functions. The formations of amyloid-β (Aβ) plaques and intracellular neurofibrillary tangles (NFTs), two important pathological hallmarks of AD, have been linked to the synapse loss, neuronal degeneration and subsequent dramatic brain atrophy of AD patients [1, 2]. Although these clinical features and pathological profiles of AD have been well documented and various animal models containing AD-related genetic backgrounds have been developed, the etiological mechanisms for AD are still far from being fully understood and effective therapeutic strategies for AD are still urgently needed.
Dozens of drugs and therapeutic strategies attempting to slow or halt neuronal loss and cognitive deficiency of AD are being investigated around the world . However, only five pharmacological agents have been approved for clinical AD treatment by the Food and Drug Administration, including cholinesterase inhibitors tacrine, donepezil, galantamine, rivastigmine and N-methyl-D-aspartate (NMDA) receptor antagonist memantine . Unfortunately, all these currently available pharmacological therapeutics only relieve symptoms without affecting the major pathological characteristics of AD. Moreover, the effectiveness of these agents varies from person to person as evidenced by a moderate efficiency in no more than 20 % of patients and tolerance, noncompliance and side-effects in more than 60 % of treated patients .
Several theoretical hypotheses have been raised for elucidating the pathological mechanisms of AD, including amyloid-cascade hypothesis , tau hypothesis , mitochondrial cascade hypothesis , oxidative stress hypothesis  and neuroinflammation hypothesis . Among them, amyloid-cascade hypothesis is widely accepted as the centerpiece of AD pathology, in which Aβ is recognized as the initiating factor in AD. Previous studies have reported that Aβ plaque deposition, an early critical event of AD, triggers the downstream features of AD including tangles formation, oxidative stress, neuroinflammation and neuronal loss. Several new candidates targeting Aβ have been tested in clinical trials in past years. Unfortunately, all of these therapeutic candidates failed to improve the cognitive and functional ability of AD patients, yet caused serious side-effects [11, 12]. Therefore, a better understanding of the upstream mechanisms of AD pathology is urgently required for the discovery of novel disease-modifying therapeutic strategies.
The identification of AD causal genes resulted in the generation of more than 150 transgenic AD mouse models, by over-expressing one or more mutated genes such as human APP, PSEN1/2, or Tau . These transgenic models have greatly advanced the understanding of AD pathogenesis and promoted the findings of novel therapeutic targets and strategies for AD treatment. However, none of these transgenic models can reflect all pathogenic and clinical features of AD. Different combinations and extents of gene mutations led to a great variety of AD phenotypes [25, 26]. Although Aβ plaques and cognitive impairment were observed in almost all animal models, NFTs could only be generated by lines over-expressing human tau protein. Cholinergic neuronal loss can be observed in several lines, but massive neuronal loss in brain is rarely observed in these animal models. Based on these, in the current stage transgenic animal models cannot fully recapitulate the progress of human AD. In addition, the transgenic animals carrying autosomal dominant familial AD (FAD) genes may have limitations in modeling sporadic AD (SAD) [27, 28]. Therefore, more representative models are needed for facilitating the fundamental AD research and exploring more efficient therapeutic strategies for AD treatment.
Progress of iPSCs research
In 2006, Yamanaka and colleagues found mouse fibroblast cells can be reprogrammed into iPSCs by using 4 transcription factors including Octamer-binding transcription factor 4 (Oct4), sex determining region Y-box 2 (Sox2), Kruppel-like factor 4 and cMyc . In 2007, this technology was successfully applied in human somatic cells . Additionally, a combination of Oct4, Sox2, NANOG and LIN28 has also been demonstrated to induce iPSCs from human somatic cells [29, 31]. After the first discovery of mouse or human iPSCs, considerable efforts have been made to develop or optimize this technology, including reprogramming cells by using fewer or newly defined factors and more efficient delivery systems.
Oct4 inhibits the expression of differentiation-related genes in ESCs [34, 35, 36] and has been reported to be sufficient to direct the reprogramming of somatic cells into iPSCs [37, 38]. Moreover, Shu et al. have found that lineage specifiers, which act as pluripotency rivals to suppress ESCs identity, can induce mouse fibroblasts into iPSCs . Lineage specifiers that are involved in mesendodermal specification (such as GATA3, GATA6, and SOX7) and ectodermal specification (such as SOX1, SOX3, and GMNN) can synergistically induce pluripotency in the absence of Oct4 and Sox2, suggesting a “seesaw effect” of the lineage specifiers in cell reprogramming. Additionally, more and more novel reprogramming factors have been identified as pluripotency-associated factors or maternal factors, such as PR domain-containing 14, Sall4, Esrrb, Utf1, Tet1, Tet2, Gli-similar protein 1 and inhibitors of differentiation 3 [40, 41, 42, 43, 44, 45, 46, 47, 48].
Manipulations of microRNAs (miRs), such as miR-291-3p, miR-294 and miR-295, have been reported to increase the efficiency of reprogramming without the presence of cMyc . Anokye-Danso and colleagues have also found that miR-302-367 can replace traditional reprogramming factors to reprogram mouse and human somatic cells into iPSCs with higher efficiency .
Besides the utilization of pluripotency transcription factors, the induction of iPSCs has been extended to involve various kinds of donor cells, including fibroblasts, glias, neural progenitors, human keratinocytes, liver and stomach cells, pancreatic-β cells, mature B lymphocytes, human amniotic fluid-derived cells, as well as cells in blood and urine [51, 52, 53, 54, 55, 56].
Additionally, the delivering strategies for inducing iPSCs have been improved. The retroviral or lentiviral vectors were routinely used to integrate the reprogramming genes into the host genome to induce iPSCs [30, 57]. Viral delivery system are efficient and reproducible in reprogramming, however, the random integration of transgenes into genome increases the risk of tumor formation and may cause mortality in chimeric and progeny mice derived from iPSCs . Transfection of linear DNA by polycistronic vectors using liposomes or electroporation can avoid viral integration, but the reprogramming efficiency of these methods is much lower than viral delivery. The piggyBac transposon delivery system is less risky because the integration of non-viral constructsis more stable than virus vectors . Furthermore, many viral integration-free systems for iPSCs generation have been established, such as adenovirus, Sendai virus, minicircle vector, episomal vectors, and direct protein delivery [60, 61, 62, 63, 64, 65]. Importantly, Hou et al. have reported that small-molecules, such as VC6T plus FSK, can replace “master genes” Sox2 and Oct4 to induce cell reprogramming [65, 66]. This chemical reprogramming strategy is relatively simple and less time-consuming, and has promising potential in generating functional desirable cell types for clinical applications.
Application of iPSCs in AD modeling
iPSCs-based AD modeling
Fibroblasts of FAD patient with mutations in PS1 and PS2
FAD-iPSCs-derived neurons have increased Aβ42 secretion; responds to γ-secretase inhibitors and modulators
Recapitulating the molecular pathogenesis of mutant PS; identification and validation of candidate drugs
FAD- and SAD-iPSCs
Fibroblasts of FAD patient with mutations in APP; sporadic AD
AD-iPSCs-derived neurons exhibited higher levels of Aβ, pTau, and active GSK-3β; β-secretase inhibitors caused significant reductions in pTau and active GSK-3β levels
The first SAD iPSC model; Demonstrating the direct relationship between APP processing in GSK-3β activation and tau phosphorylation
Fibroblasts from AD patient
AD-specific iPSCs lines
Exploring AD pathologies; screening new drugs and therapeutic regimens
Fibroblast of Down syndrome patients
Neurons generated from Down syndrome patients-iPSCs developed AD pathologies
Recapitulating AD pathogenic process including Aβ42 and hyperphosphorylated tau
PSEN1 mutant fibroblasts
produced greater ratios of Aβ42 to Aβ40; 14 genes differentially-regulated
Identify novel candidate genes during AD pathology
Human dermal fibroblasts
Aβ oligomers accumulation; elevated endoplasmic reticulum (ER) and oxidative stress;
Illustrating how patient-specific iPSCs can be useful for analyzing AD pathogenesis and evaluating drugs.
Human fibroblast carrying APP mutation (V717I)
Increased APP expression and levels of APPsβ, Aβ; increased Aβ42 and Aβ38; increase in levels of total and phosphorylated Tau
Demonstrating the direct casual relationship between elevated Aβ and hyperphosphorylated tau using Aβ neutralizing antibodies, for the first time;
Providing a model system for testing therapeutic strategies in the cell types most relevant to disease processes
Yagi et al. firstly generated iPSCs from AD patients carrying familial mutations in PSEN1 (A246E) and PSEN2 (N141I) and reported that these FAD-derived iPSCs had an increased Aβ42 production and an elevated ratio of Aβ42/Aβ40 . Then, Israel et al. generated iPSCs lines from two SAD patients (named as sAD1/sAD2) and two FAD patients with a duplication of APP (APPDp) . They found that neurons derived from APPDp-iPSCs line and sAD2-iPSCs line have significantly higher levels of Aβ40, increased phosphorylation of tau protein (at Thr 231) together with an elevated level of active glycogen synthase kinase-3β (aGSK-3β). Additionally, neurons from those AD-derived iPSCs (AD-iPSCs) accumulated large RAB5-positive early endosomes, which is consistent with the findings from the neurons of AD patients . More interestingly, treatment of the neurons with β-secretase inhibitors (BSI), but not γ-secretase inhibitors, could significantly reduce the levels of phospho-tau (Thr 231) and aGSK-3β, while γ-secretase inhibitors only reduced the level of Aβ40, suggesting that APP proteolytic processing, but not Aβ40, had a direct relationship with GSK-3β activation and tau phosphorylation in human neurons. Consistent with these findings, Jang et al. and Shi et al. have also generated neurons from iPSCs derived from primary fibroblast of AD patients [70, 71] and found these cells could recapitulate AD pathogenic process such as Aβ42 and hyperphosphorylated tau and could be used for screening new drugs and therapeutic regimens.
Sproul et al. also have found a higher Aβ42/Aβ40 ratio in the neural progenitor cells (NPCs) derived from AD-iPSCs harboring PSEN1 A246E or M146L mutations . Moreover, they identified 14 genes differentially-regulated in PSEN1 NPCs molecular profiling. Among these genes, GFRA3, ISL1, DLX1, SEMA3B, and ERBB3 showed differential expression in late onset AD/Intermediate AD brains.
Kondo et al. generated seven AD-iPSCs lines, including three lines from a patient carrying APP E693 deletion (APP E693d), two lines from a patient harboring APP V717L mutation (APP V717L), and two lines from a SAD patient . The authors found that Aβ oligomers accumulated in neurons derived from APP E693d-iPSCs and in neurons and astrocytes derived from one of the two SAD-iPSCs lines, which could be reduced by BSI. Furthermore, they found that the stress responses in the AD neural cells were alleviated by BSI and docosahexaenoic acid treatment. This study illustrates the possible application of patient-specific iPSCs for screening anti-AD drugs and classifying AD patients.
Muratore et al. generated four iPSCs lines from two FAD patients carrying APP V717I mutation and differentiated them into neurons expressing forebrain neuron marker . Both β- and γ-secretase cleavage of APP were affected by this mutation. Elevated β-secretase cleavage of APP led to an increased level of both sAPPβ and Aβ, while the alteration of the initial cleavage site of γ-secretase resulted in an increased Aβ42 and Aβ38. Moreover, they found that the levels of total and phosphorylated tau were increased in neurons derived from AD patient. Furthermore, Aβ-specific antibodies could reverse the phenotype of increased total tau in AD-iPSCs derived neurons. These findings indicate that the tau-related changes are relevant to Aβ phenotype and the increased tau might be a consequence of Aβ generation, which is consistent with the amyloid-cascade hypothesis of AD.
Furthermore, forebrain cholinergic neuron (FBCN) loss is directly relevant to the memory and cognition deficits in AD. Therefore, generation of FBCNs from AD patient-specific iPSCs is crucial for disease modeling in vitro and for the development of novel AD therapies. Based on this, Duan et al. have recently reported that FBCNs derived from SAD-iPSCs showed typical AD biochemical features as evidenced by an increased Aβ42/Aβ40 ratio and a higher susceptibility to glutamate-mediated cell death .
Down syndrome (DS) patients with early-onset dementia share similar neurodegenerative features with those of AD. Chang et al. have recently found that accumulated amyloid deposits, tau protein hyperphosphorylation and tau intracellular redistribution emerged rapidly in DS-iPSCs-derived neurons within 45 days but not in normal ESCs-derived neurons, suggesting DS-iPSC-derived neural cells can serve as an ideal cellular model of DS and AD and have potential for high-throughput screening of therapeutic candidates .
Challenges and future perspectives of iPSCs in AD disease modeling
The above mentioned research findings reveal several pathological features of AD, including Aβ generation and tau-phosphorylation, in AD-iPSCs derived from FAD and SAD patients, indicating the potential application of iPSCs technology in AD modeling and drug screening. However, there are still several concerns regarding AD-iPSCs models.
First of all, although iPSCs could serve as a promising avenue for disease modeling, the molecular principles for this technique, particularly in human cells, still remain poorly understood due to donor-to-donor variability and intercellular heterogeneity. In the study from Israel et al., only one of the two SAD-iPSCs lines has the same phenotypes as the APPDp-iPSCs line. Similarly, Kondo et al. have also found that seven AD-iPSCs lines with APP E693 deletion or APP V717L mutation or SAD did not always recapitulate the same phenotypes . These inconsistencies might suggest that although there are similar mechanisms underlying the pathogenesis of FAD or SAD, a larger sample size is still required to investigate the comprehensive and robust heterogeneity of AD phenotypes in future study. In addition, although AD patient-derived human neurons have shown elevated levels of toxic Aβ species and phosphorylated tau, they also could not recapitulate Aβ plaques or tau tangles. One of the possible reasons for this might be the lack of a proper cell culture system, which mimics the in vivo condition and provides a better microenvironment to achieve enough pathogenic Aβ accumulation, as observed in human AD patients and transgenic AD mouse models. Recently, Kim et al. have found that robust Aβ and tau pathologies could be achieved in a 3-dimension human neural cell culture models . Although this model was based on genetically engineered human neural stem cell line, not iPSCs, it may provide a promising tool for human AD iPSCs models.
Secondly, the neural cells differentiated from iPSCs displayed AD pathological hallmarks in less than two months, suggesting that disease-related cells may be more susceptible to display the hallmarks of disease in cell culture dishes than in patients’ brains. However, there also remains the question that whether the one or two cell types differentiated from iPSCs can represent all complicate phenotypes of AD. In addition, the cells exhibited the pathological changes of AD, but synapse loss or neuronal degeneration was rarely observed. It has been reported that AD is a complex disease that affects both neuronal and glial activities and glia participates in Aβ clearance and inflammation in AD . Therefore, further studies of glial cells derived from AD-iPSCs can facilitate the discovery of the exact mechanisms underling AD pathogenesis.
Thirdly, in these studies of AD-iPSCs, iPSCs derived from healthy individuals or family members were used as controls, which may have totally different genetic background from the AD-iPSCs. This kind of controls is not the most appropriate approach in disease modeling assays. Hence, isogenic iPSCs derived from AD-iPSCs, in which the mutations have been corrected to wild-type, are the most appropriate controls. Nowadays, isogenic, mutation-corrected control cell lines generated by transcription activator-like effector nucleases (TALENs) or clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein (Cas) mediated genomic editing technology has been applied in human diseases, such as ALS, and tumors [79, 80].
Overall, AD-iPSC lines from more AD patients and further studies using both AD-iPSC-derived neuron and glial cells and isogenic controls can provide tools to discover more accurate features and mechanisms of AD.
iPSCs-based cell replacement therapy for AD: the mechanisms and rationales
iPSCs have great potential in cell transplantation therapy of neurodegenerative diseases including AD. Transplantable neural progenitors or neurons can be generated from ESCs and iPSCs [81, 82]. NPCs derived from ESCs or iPSCs can be further differentiated into neurons, astrocytes or oligodendrocytes, which provide promising aspect for cell-replacement therapy of various neurodegenerative disorders including AD.
The dysfunction of neurogenesis has been found in AD mouse models, indicating that the worsened imbalance between neurogenesis and neuronal loss may contribute to the pathogenesis of AD . It is generally accepted that adult neurogenesis primarily occurs in two sites important for learning and memory, the subventricular zone (SVZ) of the lateral ventricles and the subgranular zone (SGZ) of the dentate gyrus (DG) of the hippocampus. Wang et al. have reported that AD transgenic mice harboring PSEN1P117L show a decreased survival of NPCs, leading to a reduced production of new neurons. In addition, the reduced adult neurogenesis in DG has been suggested to be correlated with an impaired contextual fear conditioning in mouse [84, 85, 86, 87]. In APP V717F mice, an age-dependent decrease of cell proliferation in SGZ of DG was also observed . Research reports suggest that neurogenesis was significantly enhanced as a self-repairing mechanism to compensate for the early onset of neurodegeneration; however, the survival of newly generated neurons was impaired following neurodegeneration progression . Interestingly, although the cellular composition and morphological organization of the SVZ in human and non-human primates differ from those of rodents [90, 91], the proliferation and migration of NPCs in the SVZ of young APP transgenic mice have also been reported to be greatly decreased , suggesting that Aβ plaques might be involved in the impaired neurogenesis in AD mouse model. However, it has been reported that the decreased NPCs and neuroblasts as wells as severely impaired proliferation and differentiation of NPCs occurred preceding the onset of amyloid deposition and memory impairment in 2-month-old APPswe/PSEN1ΔE9 mice or triple transgenic mice carrying APPswe, PSEN1-M146V and tau-P301L mutations . These findings suggest that progressive neuronal loss and impaired neurogenesis may be important pathological events of AD.
Previous studies have found that transplanted NSCs differentiate into mature cell types and improve cognitive ability of AD animal models via various mechanisms, with or without the involvement of Aβ or tau pathologies. For instance, NSCs have been reported to rescue cognitive functions and promote synaptogenesis without altering Aβ or tau pathologies in AD mouse models [94, 95, 96]. Moreover, NSCs have also been found to attenuate the expression of proinflammatory cytokines and neuronal loss in AD model . In contrast to these research reports, Lee et al. have revealed that human NSCs transplantation reduced tau phosphorylation, down-regulated BACE1 expression and Aβ production via Akt/GSK3β signaling, and decreased the expression of inflammatory mediators through deactivation of microglia . As a primary source of NSCs, iPSCs, especially human-derived iPSCs, may provide a promising strategy for cell-replacement therapy of AD.
It is likely that the transplantation of NSCs can provide not only a direct cell-replacing strategy for AD therapy, but also can be used as vehicles for the delivery of potential therapeutic agents, including neprilysin, insulin-degrading enzyme, plasmin and cathepsin B, to reverse AD pathologies [99, 100]. It is suggested that the future NSCs- or iPSCs-based cell therapy in AD should focus on such indirect mechanisms [101, 102, 103].
iPSCs-based cell replacement therapy for AD: hints from other CNS disorders
iPSCs have great potential as cell source in cell transplantation therapy of neurodegenerative diseases [104, 105]. One of the main purposes of iPSCs-based cell replacement therapy in AD and other neurodegenerative diseases is to produce new neurons to replace those lost or function-deficient cells during disease progression or to produce glial cells to protect neurons from ongoing degeneration. Data from in vivo studies suggest that iPSCs-derived neurospheres were able to survive and differentiate into neurons, astrocytes, and oligodendrocytes, after transplantation into injured mouse spinal cord . In addition, previous research report has also indicated that after transplantation into the fetal mouse brain, NPCs derived from mouse iPSCs migrate into various brain regions and differentiate into glia and neurons , and thus are capable to integrate into preexisting functional neuronal circuitries in the CNS or compensate the degenerative neurons. Electrophysiological experiments and morphological observations demonstrate that the grafted neurons display normal neuronal activity and are functionally integrated into the host brain. All these findings support the notion that iPSCs- or iPSCs derivatives-based cell replacement therapy could be efficiently used to treat neurodegenerative diseases. Indeed, several lines of studies have tested this idea in experimental models of Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS).
It has been reported that transplanted neural stem cells in parkinsonian rat striatum can release and reuptake dopamine and alleviate PD symptoms . Human iPSCs-derived neurons can improve the functional defects of rotational asymmetry in PD rat model after transplantation . Autologous iPSCs-derived dopamine neurons can provide long-term functional recovery in monkey model of PD . In addition, glial-rich neural progenitors derived from human iPSCs can improve lifespan of ALS mice after being transplanted into the lumbar spinal cord .
As for AD, Fujiwara et al. have reported that the spatial memory of AD mice was improved significantly after grafted with human iPSCs-derived neural progenitors . In addition, Huang’s group has found that after transplantation of the embryonic medial ganglionic eminence (MGE)-derived interneuron progenitors into the hippocampal hilus of aged apoE4-KI mice, the transplanted cells developed into mature interneurons, and the neurons functionally integrated into the hippocampal circuitry and rescued learning and memory . Moreover, Nicholas et al. found that MGE-like progenitors derived from both ESCs and iPSCs could be induced to differentiate into GABAergic interneurons and displayed mature physiological properties in mouse brain up to 7 months post-transplantation . These research findings indicate that transplanted human iPSCs-derived cells can functionally rescue pathological changes in the brains of AD patients. All these preclinical progresses in the investigation of cell transplantation in neurodegenerative diseases may provide proof-of-concept for the final clinical translation of iPSCs in therapy of AD.
Although great achievements have been made for iPSCs-based cell replacement therapy, one major challenge is teratoma formation. It has been demonstrated in the mouse system that iPSCs-derived chimeras frequently develop tumors, which should be carefully evaluated after transplantation before clinical application. Takahashi et al. calculated that approximately 20 % of the mice derived from iPSCs develop tumors . Transgene reactivation and incomplete reprogramming are considered as the primary causes of tumorigenesis . In order to reduce the risk of tumor formation that limits the clinic application of iPSCs, many studies have provided strategies. Wang et al. have introduced a mifepristone-regulated caspase-1 expression system to selectively eliminate tumor cells derived from undifferentiated ESCs but not differentiated dopamine neurons . Cui et al. have identified that the suppression of canonical wingless-type MMTV integration site family (WNT) signaling pathway can reduce the tumorigenicity and substantially improved retinal integration of ESCs-derived retinal progenitor cells transplanted in mice . In addition, Nori et al. have recently suggested that integration-free iPSCs should be chosen to avoid tumorigenesis . Overall, these progresses of iPSCs research can provide new avenue for the clinical translation of cell transplantation therapy against various neurodegenerative diseases including AD.
AD patient-specific iPSCs-derived neurons or glia cells can recapture not only familial, but also sporadic form of AD. Moreover, iPSCs provide unique platforms to detect the early-disease phenotypes during neurogenesis or neurodegeneration which may point towards underlying pathogenic mechanisms of AD. In addition, isogenic iPSCs of AD-iPSCs can be obtained by TALEN- or CRISPR/Cas-mediated genetic repairing technology. Genetically repaired AD-iPSCs can serve as more appropriate control cells for disease modeling and cells transplantation. Altogether, even though there are several challenges in the clinical usage of iPSCs technology, the recent promising achievements in this field will contribute significantly for exploring molecular mechanisms of AD and promoting clinical AD therapy.
This work was supported by grants from the National Natural Sciences Foundation of China (81430021 and 81370470), the Program for Liaoning Innovative Research Team in University (LT2015009).
- 11.Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR. Bapineuzumab 301 and 302 Clinical Trial Investigators. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370(4):322–33.PubMedPubMedCentralCrossRefGoogle Scholar
- 12.Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R, Alzheimer's Disease Cooperative Study Steering Committee; Solanezumab Study Group. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370(4):311–21.PubMedCrossRefGoogle Scholar
- 18.Willette AA, Bendlin BB, Starks EJ, Birdsill AC, Johnson SC, Christian BT, Okonkwo OC, La Rue A, Hermann BP, Koscik RL, Jonaitis EM, Sager MA, Asthana S.. Association of insulin resistance with cerebral glucose uptake in late middle-aged adults at risk for Alzheimer Disease. JAMA Neurol. 2015;72(9):1013–20.PubMedCrossRefGoogle Scholar
- 37.Krohne TU, Westenskow PD, Kurihara T, Friedlander DF, Lehmann M, Dorsey AL, Li W, Zhu S, Schultz A, Wang J, Siuzdak G, Ding S, Friedlander M. Generation of retinal pigment epithelial cells from small molecules and OCT4 reprogrammed human induced pluripotent stem cells. Stem Cells Transl Med. 2012;1(2):96–109.PubMedPubMedCentralCrossRefGoogle Scholar
- 43.Chia NY, Chan YS, Feng B, Lu X, Orlov YL, Moreau D, Kumar P, Yang L, Jiang J, Lau MS, Huss M, Soh BS, Kraus P, Li P, Lufkin T, Lim B, Clarke ND, Bard F, Ng HH. A genome-wide RNAi screen reveals determinants of human embryonic stem cell identity. Nature. 2010;468(7321):316–20.PubMedCrossRefGoogle Scholar
- 46.Hu X, Zhang L, Mao SQ, Li Z, Chen J, Zhang RR, Wu HP, Gao J, Guo F, Liu W, Xu GF, Dai HQ, Shi YG, Li X, Hu B, Tang F, Pei D, Xu GL. Tet and TDG mediate DNA demethylation essential for mesenchymal-to-epithelial transition in somatic cell reprogramming. Cell Stem Cell. 2014;14(4):512–22.PubMedCrossRefGoogle Scholar
- 53.Montserrat N, Ramirez-Bajo MJ, Xia Y, Sancho-Martinez I, Moya-Rull D, Miquel-Serra L, Yang S, Nivet E, Cortina C, Gonzalez F, Izpisua Belmonte JC, Campistol JM. Generation of induced pluripotent stem cells from human renal proximal tubular cells with only two transcription factors, OCT4 and SOX2. J Biol Chem. 2012;287(29):24131–8.PubMedPubMedCentralCrossRefGoogle Scholar
- 55.Zhou T, Benda C, Duzinger S, Huang Y, Li X, Li Y, Guo X, Cao G, Chen S, Hao L, Chan YC, Ng KM, Ho JC, Wieser M, Wu J, Redl H, Tse HF, Grillari J, Grillari-Voglauer R, Pei D, Esteban MA. Generation of induced pluripotent stem cells from urine. J Am Soc Nephrol. 2011;22(7):1221–8.PubMedPubMedCentralCrossRefGoogle Scholar
- 57.Sommer AG, Rozelle SS, Sullivan S, Mills JA, Park SM, Smith BW, Iyer AM, French DL, Kotton DN, Gadue P, Murphy GJ, Mostoslavsky G. Generation of human induced pluripotent stem cells from peripheral blood using the STEMCCA lentiviral vector. J Vis Exp. 2012;(68). doi: 10.3791/4327
- 59.Urschitz J, Kawasumi M, Owens J, Morozumi K, Yamashiro H, Stoytchev I, Marh J, Dee JA, Kawamoto K, Coates CJ, Kaminski JM, Pelczar P, Yanagimachi R, Moisyadi S. Helper-independent piggyBac plasmids for gene delivery approaches: strategies for avoiding potential genotoxic effects. Proc Natl Acad Sci U S A. 2010;107(18):8117–22.PubMedPubMedCentralCrossRefGoogle Scholar
- 60.Fink KD, Rossignol J, Lu M, Leveque X, Hulse TD, Crane AT, Nerriere-Daguin V, Wyse RD, Starski PA, Schloop MT, Dues DJ, Witte SJ, Song C, Vallier L, Nguyen TH, Naveilhan P, Anegon I, Lescaudron L, Dunbar GL. Survival and differentiation of adenovirus-generated induced pluripotent stem cells transplanted into the rat striatum. Cell Transplant. 2014;23(11):1407–23.PubMedCrossRefGoogle Scholar
- 68.Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, Hefferan MP, Van Gorp S, Nazor KL, Boscolo FS, Carson CT, Laurent LC, Marsala M, Gage FH, Remes AM, Koo EH, Goldstein LS. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature. 2012;482(7384):216–20.PubMedPubMedCentralGoogle Scholar
- 69.Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, Nixon RA. Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am J Pathol. 2000;157(1):277–86.PubMedPubMedCentralCrossRefGoogle Scholar
- 72.Sproul AA, Jacob S, Pre D, Kim SH, Nestor MW, Navarro-Sobrino M, Santa-Maria I, Zimmer M, Aubry S, Steele JW, Kahler DJ, Dranovsky A, Arancio O, Crary JF, Gandy S, Noggle SA. Characterization and molecular profiling of PSEN1 familial Alzheimer's disease iPSC-derived neural progenitors. PLoS One. 2014;9(1):e84547.PubMedPubMedCentralCrossRefGoogle Scholar
- 73.Kondo T, Asai M, Tsukita K, Kutoku Y, Ohsawa Y, Sunada Y, Imamura K, Egawa N, Yahata N, Okita K, Takahashi K, Asaka I, Aoi T, Watanabe A, Watanabe K, Kadoya C, Nakano R, Watanabe D, Maruyama K, Hori O, Hibino S, Choshi T, Nakahata T, Hioki H, Kaneko T, Naitoh M, Yoshikawa K, Yamawaki S, Suzuki S, Hata R, Ueno S, Seki T, Kobayashi K, Toda T, Murakami K, Irie K, Klein WL, Mori H, Asada T, Takahashi R, Iwata N, Yamanaka S, Inoue H.. Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Abeta and differential drug responsiveness. Cell Stem Cell. 2013;12(4):487–96.PubMedCrossRefGoogle Scholar
- 77.Choi SH, Kim YH, Hebisch M, Sliwinski C, Lee S, D'Avanzo C, Chen H, Hooli B, Asselin C, Muffat J, Klee JB, Zhang C, Wainger BJ, Peitz M, Kovacs DM, Woolf CJ, Wagner SL, Tanzi RE, Kim DY. A three-dimensional human neural cell culture model of Alzheimer's disease. Nature. 2014;515(7526):274–8.PubMedPubMedCentralCrossRefGoogle Scholar
- 81.Klincumhom N, Pirity MK, Berzsenyi S, Ujhelly O, Muenthaisong S, Rungarunlert S, Tharasanit T, Techakumphu M, Dinnyes A. Generation of neuronal progenitor cells and neurons from mouse sleeping beauty transposon-generated induced pluripotent stem cells. Cell Reprogram. 2012;14(5):390–7.PubMedPubMedCentralGoogle Scholar
- 82.Sareen D, Gowing G, Sahabian A, Staggenborg K, Paradis R, Avalos P, Latter J, Ornelas L, Garcia L, Svendsen CN. Human induced pluripotent stem cells are a novel source of neural progenitor cells (iNPCs) that migrate and integrate in the rodent spinal cord. J Comp Neurol. 2014;522(12):2707–28.PubMedPubMedCentralCrossRefGoogle Scholar
- 83.Haughey NJ, Liu D, Nath A, Borchard AC, Mattson MP. Disruption of neurogenesis in the subventricular zone of adult mice, and in human cortical neuronal precursor cells in culture, by amyloid beta-peptide: implications for the pathogenesis of Alzheimer's disease. Neuromolecular Med. 2002;1(2):125–35.PubMedCrossRefGoogle Scholar
- 84.Hallett PJ, Deleidi M, Astradsson A, Smith GA, Cooper O, Osborn TM, Sundberg M, Moore MA, Perez-Torres E, Brownell AL, Schumacher JM, Spealman RD, Isacson O. Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson's disease. Cell Stem Cell. 2015;16(3):269–74.PubMedPubMedCentralCrossRefGoogle Scholar
- 85.Kondo T, Funayama M, Tsukita K, Hotta A, Yasuda A, Nori S, Kaneko S, Nakamura M, Takahashi R, Okano H, Yamanaka S, Inoue H. Focal transplantation of human iPSC-derived glial-rich neural progenitors improves lifespan of ALS mice. Stem Cell Reports. 2014;3(2):242–9.PubMedPubMedCentralCrossRefGoogle Scholar
- 87.Wen PH, Hof PR, Chen X, Gluck K, Austin G, Younkin SG, Younkin LH, DeGasperi R, Gama Sosa MA, Robakis NK, Haroutunian V, Elder GA. The presenilin-1 familial Alzheimer disease mutant P117L impairs neurogenesis in the hippocampus of adult mice. Exp Neurol. 2004;188(2):224–37.PubMedCrossRefGoogle Scholar
- 92.Veeraraghavalu K, Choi SH, Zhang X, Sisodia SS. Presenilin 1 mutants impair the self-renewal and differentiation of adult murine subventricular zone-neuronal progenitors via cell-autonomous mechanisms involving notch signaling. J Neurosci. 2010;30(20):6903–15.PubMedPubMedCentralCrossRefGoogle Scholar
- 94.Blurton-Jones M, Kitazawa M, Martinez-Coria H, Castello NA, Muller FJ, Loring JF, Yamasaki TR, Poon WW, Green KN, LaFerla FM. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci U S A. 2009;106(32):13594–9.PubMedPubMedCentralCrossRefGoogle Scholar
- 95.Ager RR, Davis JL, Agazaryan A, Benavente F, Poon WW, LaFerla FM, Blurton-Jones M. Human neural stem cells improve cognition and promote synaptic growth in two complementary transgenic models of Alzheimer's disease and neuronal loss. Hippocampus. 2015;25(7):813–26.PubMedPubMedCentralCrossRefGoogle Scholar
- 104.Hargus G, Ehrlich M, Arauzo-Bravo MJ, Hemmer K, Hallmann AL, Reinhardt P, Kim KP, Adachi K, Santourlidis S, Ghanjati F, Fauser M, Ossig C, Storch A, Kim JB, Schwamborn JC, Sterneckert J, Schöler HR, Kuhlmann T, Zaehres H. Origin-dependent neural cell identities in differentiated human iPSCs in vitro and after transplantation into the mouse brain. Cell Rep. 2014;8(6):1697–703.PubMedCrossRefGoogle Scholar
- 105.Hicks AU, Lappalainen RS, Narkilahti S, Suuronen R, Corbett D, Sivenius J, Hovatta O, Jolkkonen J. Transplantation of human embryonic stem cell-derived neural precursor cells and enriched environment after cortical stroke in rats: cell survival and functional recovery. Eur J Neurosci. 2009;29(3):562–74.PubMedCrossRefGoogle Scholar
- 106.Tsuji O, Miura K, Okada Y, Fujiyoshi K, Mukaino M, Nagoshi N, Kitamura K, Kumagai G, Nishino M, Tomisato S, Higashi H, Nagai T, Katoh H, Kohda K, Matsuzaki Y, Yuzaki M, Ikeda E, Toyama Y, Nakamura M, Yamanaka S, Okano H. Therapeutic potential of appropriately evaluated safe-induced pluripotent stem cells for spinal cord injury. Proc Natl Acad Sci U S A. 2010;107(28):12704–9.PubMedPubMedCentralCrossRefGoogle Scholar
- 107.Wernig M, Zhao JP, Pruszak J, Hedlund E, Fu D, Soldner F, Broccoli V, Constantine-Paton M, Isacson O, Jaenisch R. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci U S A. 2008;105(15):5856–61.PubMedPubMedCentralCrossRefGoogle Scholar
- 108.Kang X, Xu H, Teng S, Zhang X, Deng Z, Zhou L, Zuo P, Liu B, Liu B, Wu Q, Wang L, Hu M, Dou H, Liu W, Zhu F, Li Q, Guo S, Gu J, Lei Q, Lü J, Mu Y, Jin M, Wang S, Jiang W, Liu K, Wang C, Li W, Zhang K, Zhou Z. Dopamine release from transplanted neural stem cells in Parkinsonian rat striatum in vivo. Proc Natl Acad Sci U S A. 2014;111(44):15804–9.PubMedPubMedCentralCrossRefGoogle Scholar
- 110.Fujiwara N, Shimizu J, Takai K, Arimitsu N, Saito A, Kono T, Umehara T, Ueda Y, Wakisaka S, Suzuki T, Suzuki N. Restoration of spatial memory dysfunction of human APP transgenic mice by transplantation of neuronal precursors derived from human iPS cells. Neurosci Lett. 2013;557 Pt B:129–34.PubMedCrossRefGoogle Scholar
- 111.Tong LM, Djukic B, Arnold C, Gillespie AK, Yoon SY, Wang MM, Zhang O, Knoferle J, Rubenstein JL, Alvarez-Buylla A, Huang Y. Inhibitory interneuron progenitor transplantation restores normal learning and memory in ApoE4 knock-in mice without or with Abeta accumulation. J Neurosci. 2014;34(29):9506–15.PubMedPubMedCentralCrossRefGoogle Scholar
- 112.Nicholas CR, Chen J, Tang Y, Southwell DG, Chalmers N, Vogt D, Arnold CM, Chen YJ, Stanley EG, Elefanty AG, Sasai Y, Alvarez-Buylla A, Rubenstein JL, Kriegstein AR. Functional maturation of hPSC-derived forebrain interneurons requires an extended timeline and mimics human neural development. Cell Stem Cell. 2013;12(5):573–86.PubMedPubMedCentralCrossRefGoogle Scholar
- 117.Nori S, Okada Y, Nishimura S, Sasaki T, Itakura G, Kobayashi Y, Renault-Mihara F, Shimizu A, Koya I, Yoshida R, et al. Long-term safety issues of iPSC-based cell therapy in a spinal cord injury model: oncogenic transformation with epithelial-mesenchymal transition. Stem Cell Reports. 2015;4(3):360–73.PubMedPubMedCentralCrossRefGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.